Nouscom is developing NOUS-209, a neoantigen-based immunotherapy designed to prevent cancers in carriers of Lynch syndrome. The Basel-based biotech has closed a Series D round of USD 135 million, co-led by M Ventures and Revelation Partners, to fund a global clinical trial towards registration.
- Announced on
- Round
- Series C and later
- Amount
- USD 135 M
- Location
- Basel, canton of Basel-Stadt
- Sector
- Biotech & life sciences
Investors
- M Ventures lead
- Revelation Partners lead
- Angelini Industries
- European Investment Bank
- Neva SGR
- 5AM Ventures
- Andera Partners
- Angelini Ventures
- Bpifrance
- CDP Venture Capital
- EQT Life Sciences
- Indaco Venture Partners
- Panakes Partners
- Versant Ventures
- XGEN Ventures
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic